Anti-Phospholipase C Protein 4 (internal region) polyclonal antibody

Background: An accumulating amount of evidence has suggested that there is a contributive role of sympathetic nervous hyperactivity in the pathogenesis of chronic kidney disease (CKD). alpha 1-AR promotes an increase in calcium levels in podocytes and adjusts podocyte contraction. Changes in TRPC6 expression and function can directly affect the podocyte cytoskeleton, which is a key component in podocyte injury. This study proposed to clarify the correlation between alpha 1-AR activation-induced signal cascade reaction and TRPC6 in human podocytes. Methods: Human podocytes were incubated with the calcium probe Fluo-3/AM. Next, the effects of the alpha 1-AR agonists or antagonists and nonselective TRPC6 blockers on intracellular calcium were observed under laser confocal microscopy. FITC-phalloidin was employed to stain podocytes, and the change of F-actin under the alpha 1-AR activation condition was observed. Results: The alpha 1-AR agonist PE (phenylephrine hydrochloride) induced an increase in intracellular Ca2+ ([Ca2+]i) in human podocytes. Moreover, the downregulation of TRPC6 by siRNA or TRPC blocker could attenuate the PE-induced [Ca2+]i elevation in a phospholipase C (PLC)-dependent pattern. When podocytes were stimulated to the PE, their F-actin.ber cytoskeletal structure was lost. PE subsequently increased the expression of RhoA, and the TRPC6-dependent Ca2+ influx was involved in this process. The abnormal activation of RhoA could result in disturbance of the podocyte skeleton structure, thus leading to podocyte injury. Conclusions: We concluded that TRPC6 is involved in alpha 1-AR activation-induced calcium signal changes in podocytes. Meanwhile, the alpha 1-AR agonists can destroy the cell's cytoskeletal structure, which is mediated by TRPC6 via the RhoA/ROCK pathway.

Background: Immune complexes (ICs) bind to and activate platelets via Fc gamma RIIA, causing patients to experience thrombocytopenia, as well as an increased risk of forming occlusive thrombi. Although platelets have been shown to mediate IC-induced pathologies, the mechanisms involved have yet to be fully elucidated. We identified that apoptosis signal-regulating kinase 1 (ASK1) is present in both human and mouse platelets and potentiates many platelet functions. Objectives: Here we set out to study ASK1's role in regulating IC-mediated platelet functions in vitro and IC-induced pathologies using an in vivo mouse model. Methods: Using human platelets treated with an ASK1-specific inhibitor and platelets fromFCGR2A/Ask1(-/-) transgenic mice, we examined various platelet functions induced by model ICs in vitro and in vivo. Results: We found that ASK1 was activated in human platelets following cross-linking of Fc gamma RIIA using either anti-hCD9 or IV.3 + goat-anti-mouse. Although genetic deletion or inhibition of ASK1 significantly attenuated anti-CD9-induced platelet aggregation, activation of the canonical Fc gamma RIIA signaling targets Syk and PLC gamma 2 was unaffected. We further found that anti-mCD9-induced cPla(2) phosphorylation and TxA(2) generation is delayed in Ask1 null transgenic mouse platelets leading to diminished delta-granule secretion. In vivo, absence of Ask1 protected FCGR2Atransgenic mice from thrombocytopenia, thrombosis, and systemic shock following injection of anti-mCD9. In whole blood microfluidics, platelet adhesion and thrombus formation on fibrinogen was enhanced by Ask1. Conclusions: These findings suggest that ASK1 inhibition may be a potential target for the treatment of IC-induced shock and other immune-mediated thrombotic disorders.